A New Era in PROTAC Drug Development: Potential Alone Is No Longer Sufficient

Proteolysis targeting chimeras (PROTACs) have recently moved beyond being a scientific novelty and are transitioning into a clinical treatment…

The mere power of these drug candidates to degrade disease-causing proteins is no longer accepted as a sufficient justification for them to become viable drugs. In the later stages of the development process…